Margarita Irizarry-Ramirez
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 3 | 2017 | 935 | 0.770 |
Why?
|
| Prostatectomy | 2 | 2017 | 63 | 0.700 |
Why?
|
| Prostate | 2 | 2017 | 154 | 0.650 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 14 | 0.530 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 97 | 0.520 |
Why?
|
| Triglycerides | 1 | 2015 | 138 | 0.510 |
Why?
|
| Body Mass Index | 3 | 2015 | 854 | 0.390 |
Why?
|
| Obesity | 2 | 2015 | 1067 | 0.340 |
Why?
|
| Laryngeal Neoplasms | 1 | 2008 | 11 | 0.330 |
Why?
|
| Thyrotropin | 1 | 2008 | 17 | 0.310 |
Why?
|
| Spinal Cord Injuries | 2 | 2005 | 56 | 0.300 |
Why?
|
| Spinal Cord | 2 | 2005 | 94 | 0.300 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 275 | 0.260 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 26 | 0.260 |
Why?
|
| Up-Regulation | 2 | 2005 | 513 | 0.260 |
Why?
|
| Overweight | 1 | 2008 | 247 | 0.250 |
Why?
|
| Puerto Rico | 3 | 2015 | 1378 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 118 | 0.210 |
Why?
|
| Aged | 4 | 2017 | 6741 | 0.200 |
Why?
|
| Middle Aged | 4 | 2017 | 10129 | 0.160 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 114 | 0.140 |
Why?
|
| Male | 5 | 2017 | 20025 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2015 | 2026 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2015 | 534 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 628 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 2379 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 767 | 0.110 |
Why?
|
| Humans | 5 | 2017 | 37093 | 0.100 |
Why?
|
| Adult | 3 | 2015 | 11712 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 562 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 583 | 0.080 |
Why?
|
| Disease Progression | 1 | 2010 | 601 | 0.070 |
Why?
|
| Risk Factors | 1 | 2015 | 3562 | 0.070 |
Why?
|
| United States | 1 | 2017 | 4223 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 275 | 0.070 |
Why?
|
| Anterior Horn Cells | 1 | 2005 | 5 | 0.070 |
Why?
|
| Growth Cones | 1 | 2005 | 12 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2005 | 1207 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2005 | 26 | 0.070 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2005 | 70 | 0.070 |
Why?
|
| Optic Nerve Injuries | 1 | 2005 | 18 | 0.070 |
Why?
|
| Sex Factors | 1 | 2008 | 898 | 0.060 |
Why?
|
| Nerve Regeneration | 1 | 2005 | 40 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2005 | 124 | 0.060 |
Why?
|
| Cell Communication | 1 | 2005 | 97 | 0.060 |
Why?
|
| Female | 4 | 2008 | 20969 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2005 | 121 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1455 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1618 | 0.060 |
Why?
|
| Myosin Type II | 1 | 2003 | 18 | 0.050 |
Why?
|
| Astrocytes | 1 | 2005 | 255 | 0.050 |
Why?
|
| Receptors, Eph Family | 1 | 2002 | 4 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2003 | 206 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 2721 | 0.050 |
Why?
|
| Rats | 2 | 2005 | 3483 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 1371 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1015 | 0.040 |
Why?
|
| DNA | 2 | 2003 | 574 | 0.030 |
Why?
|
| Animals | 2 | 2005 | 15081 | 0.020 |
Why?
|
| DNA Damage | 1 | 1990 | 352 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 77 | 0.010 |
Why?
|
| Cell Wall | 1 | 2003 | 53 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2003 | 54 | 0.010 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2003 | 74 | 0.010 |
Why?
|
| Ephrins | 1 | 2002 | 2 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 2003 | 140 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 208 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 307 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 252 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 295 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 399 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 130 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2003 | 326 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 578 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 893 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 1742 | 0.010 |
Why?
|
| Relative Biological Effectiveness | 1 | 1990 | 1 | 0.010 |
Why?
|
| Energy Transfer | 1 | 1990 | 36 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1990 | 37 | 0.010 |
Why?
|